<DOC>
	<DOC>NCT00308282</DOC>
	<brief_summary>This study is a multicenter, double-blind, study to evaluate the safety and effectiveness of treatment with LY2127399 (in addition to the standard of care treatment, methotrexate) for patients with Rheumatoid Arthritis. Patients will receive three intravenous doses of LY2127399 or placebo. Patients will participate in 10 or more visits to the study site, over 6 months. Evaluation of safety and efficacy will be conducted throughout the study.</brief_summary>
	<brief_title>A Multi-Site Study to Evaluate the Safety and Effect of Study Drug on Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Male or female between the ages of 18 and 75 years Have given written informed consent approval Women must not be at risk to become pregnant during study participation Diagnosis of Rheumatoid Arthritis Current, regular use of Methotrexate, at a stable dose Use of excluded medications (reviewed by study doctor) Surgical treatment of a joint that is to be assessed in the study Are unable to ambulate; that is, confined to bed or wheelchair bound Have medical findings which, in the opinion of the study doctor, put patient at an unacceptable risk for participation in the study Have had recent or ongoing infection which, in the opinion of the study doctor put patient at an unacceptable risk for participation.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2008</verification_date>
</DOC>